Statins are widely used hypocholesterolemic drugs that inhibit 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, a rate-limiting enzyme of the mevalonate pathway whose biosynthetic end product is cholesterol. In addition to lowering circulating cholesterol, statins perturb the composition of cell membranes, resulting in disruption of lipid rafts, which function as signaling platforms in immunoreceptor signaling. Furthermore, by inhibiting protein prenylation, a process also dependent on mevalonate, statins block membrane targeting and hence activity of small GTPases, which control multiple pathways triggered by these receptors. T-cell activation is crucially dependent on Ras, Rho and Rab GTPases. Furthermore TCR signaling is orchestrated at lipid rafts, identifying T-cells as potential cellular targets of statins. Here we report that simvastatin suppresses T-cell activation and proliferation as the result of its capacity to inhibit HMG-CoA reductase. T-cell treatment with simvastatin does not affect intracellular cholesterol levels or raft integrity nor, accordingly, the initial tyrosine phosphorylation-dependent cascade. Conversely, inhibition of protein prenylation by simvastatin results in a dramatic impairment in the pathways regulated by small GTPases, including the Ras/MAP kinase pathway, the Rac/stress kinase pathway, and the Rab-dependent pathway of receptor endocytosis. The results identify Ras superfamily GTPases as strategic molecular targets in T-cell immunosuppression by statins.
anchored proteins and glycosphingolipids to the cell surface, transport from the endosomes to the Golgi apparatus, and internalization (4) . Furthermore, the tightly packed lipid environment of rafts favors their interactions with the saturated acyl chains of GPI-anchored proteins, as well as with the lipid moieties of important cytosolic and transmembrane proteins implicated in receptor signal transduction, including Src kinases, small and heterotrimeric GTP binding proteins, and transmembrane adaptors (4) . In agreement with their proposed role as signaling platforms, lipid raft disruption inhibits tyrosine kinase-dependent signaling cascades triggered by immunoreceptors (5) . Statins have been shown to impair lipid rafts as the result of their cholesterol-lowering activity (6) , suggesting a potential inhibitory role of these drugs on tyrosine kinase receptor coupled signaling pathways.
Mevalonic acid is also a limiting intermediate in the biosynthesis of a number of cellular isoprenoids, some of which become post-translationally incorporated into specific proteins (2, 7) . Among these, of particular relevance to cell growth, survival, and differentiation are the Ras, Rho, and Rab family GTPases (8) (9) (10) . Prenylation, which results in membrane localization of these proteins, is essential for their function (7) . Because of their inhibitory activity on HMGCoA reductase, statins impair lipid modification-and, hence, membrane localization-of small GTPases (11, 12) . Therefore, beside their capacity to lower circulating cholesterol levels, statins perturb the composition of cell membranes and inhibit protein prenylation; as such they are likely to have profound effects on key cellular processes. Statins have indeed been reported to inhibit proliferation, differentiation, and migration and to promote apoptosis in a number of cellular models (11) (12) (13) .
Among the targets of statins are many cell populations of the immune and vascular systems. Statins harbor significant anti-inflammatory activities, both on macrophages and neutrophils as well as on endothelial cells (11, 12) . Immunomodulation by statins results largely from their capacity to inhibit expression of proinflammatory proteins, including the cytokines TNFα, IL-1β, and IL-6; the chemoattractants IL-8, RANTES, and MCP-1; and proinflammatory enzymes such as COX-2 (11, 12) . Furthermore, expression of endothelial NOS, of the metalloproteases MMP-1, MMP-3, MMP-9, as well as of tissue factor and PAI-1, is modulated by statins (11, 12) , which accounts at least in part for the beneficial effects of these drugs on plaque stabilization in atherosclerosis (14) . Modulation of gene expression by statins has been correlated to inhibition of NF-κB and to enhancement of the activity of transcription factors, which antagonize proinflammatory gene expression, including Oct-1 and the PPAR family transcription factors (11, 12) . In this context, statins have been shown to synergize with fibrates, a class of synthetic agonistic ligands of PPARs (15) . The anti-inflammatory activities of statins appear to result largely from their capacity to inhibit prenylation of Rho family GTPases (16) (17) (18) (19) (20) (21) , in agreement with the key role of these proteins in the activation of the stress kinase pathways that control proinflammatory gene expression (22) .
Additional immunomodulatory activities of statins involve suppression of T-cell activation. Two main mechanisms have been proposed to underlie statin-mediated immunosuppression. The first is indirect and results from inhibition of inducible MHCII expression on macrophages and endothelial cells promoted by IFNγ (23) . The second is independent of the capacity of statins to inhibit HMG-CoA reductase and involves direct binding of some statins to LFA-1, a molecule that not only promotes leukocyte adhesion but also delivers a strong costimulatory signal essential for T-cell activation (24) . Statin binding prevents the interaction of LFA-1 with its ligand ICAM-1 via an allosteric mechanism that locks the receptor in an inactive conformation (25) . Furthermore, statins have been recently shown to modulate T-cell differentiation by skewing T-cell polarization towards the Th2 phenotype in a Th1-mediated central nervous system disease model of multiple sclerosis, resulting in suppression of antigen specific T-cell activation and reversal of paralysis (26) .
Although LFA-1 inhibition is bound to play a major role in the immunosuppressive activity of some statins on T-cells, the essential contribution of lipid rafts as sites of assembly of the TCR signaling cascade, as well as the requirement for Ras and Ras-related GTPases in TCR signal transduction (27) , suggest that statins might have a broader array of molecular targets in T-cell activation. Here we have investigated the impact of statin treatment on TCR signal transduction. The data show that simvastatin profoundly affects the TCR signaling cascade by selectively impairing the function of Ras, Rho, and Rab GTPases in the absence of significant perturbation of lipid rafts.
MATERIALS AND METHODS

Cells, antibodies, and reagents
Cells included the Jurkat T-lymphoma line and peripheral blood lymphocytes from healthy donors. PBMC were isolated from whole blood by density centrifugation on Ficoll-Paque (Amersham Biosciences Europe GmbH, Milan, Italy) and depleted of macrophages by adherence. Phosphospecific antibodies recognizing the phosphorylated active forms of Raf, MEK, Erk1/Erk2, and p38 were from Cell Signaling Technology (Beverly, MA). Anti-p38, antiErk2, anti-CD3ζ, and anti-CD3ε mAb were from Santa Cruz Biotechnology (Santa Cruz, CA), anti-phosphotyrosine mAb, anti-Lck, anti-Fyn, anti-Vav, anti-ZAP-70, anti-LAT, anti-Pak, antiRas, and anti-Rac polyclonal and monoclonal antibodies from Upstate Biotechnology Inc (Boston, MA), anti-actin, and anti-tubulin mAb from Amersham Biosciences Europe GmbH. A mAb suitable for immunoprecipitation of tyrosine phosphorylated CD3ζ was kindly provided by M. Banyiash. Fluorochrome-labeled anti-human CD69 and CD25 and unlabeled anti-CD28 were purchased from BD Biosciences (Leiden, The Netherlands). IgG antibodies from OKT3 (anti-CD3; American Type Culture Collection, Manassas, VA) hybridoma supernatants were purified on Mabtrap (Amersham Biosciences Europe GmbH) and titrated by flow cytometry. Secondary unlabeled antibodies were from Cappel (Durham, NC), secondary peroxidase-labeled antibodies were from Amersham Biosciences Europe GmbH. Cholera toxin B (CtxB) and anti-CtxB mouse mAb were kindly provided by T. Hirst. Brij-58, Brij-98, Triton X-100, mevalonate, farnesylpyrophosphate, geranylgeranylpyrophosphate, squalene, and methyl-β-cyclodextrin were purchased from Sigma-Aldrich srl (Milan, Italy).
Simvastatin (Merck & Co., Inc, Rahway, NJ) was resuspended at 16 mg/ml in 0.06 N NaOH in 40% ethanol and activated by heating for 2 h at 50°C. The solution was subsequently neutralized to pH 7.2 with HCl, added with an equal volume of dH 2 O to obtain a 20 mM stock, and frozen in aliquots. Cells were treated with simvastatin (10-30 µM) for 24-48 h before activation. When required, mevalonate (50-200 µM), farnesylpyrophosphate (2-10 µM), geranylgeranylpyrophosphate (10 µM), or squalene (10 µM) were added together with simvastatin. Cell viability was assessed by Trypan blue exclusion. Apoptosis was analyzed by propidium iodide staining and flow cytometric analysis of cells with subdiploid DNA content.
Activations, immunoprecipitations, in vitro binding assays, immunoblots, and metabolic labeling
Activations by cross-linking of anti-CD3 mAb were performed as described (28) . Cells (1-5 ×10 6 /sample for direct immunoblot analysis, 1-5 × 10 7 /sample for immunoprecipitations or in vitro binding assays) were lysed in 1% (v/v) Triton X-100 in 20 mM Tris-HCl, pH 8; 150 mM NaCl (in the presence of 0.2 mg/ml Na orthovanadate; 1 µg/ml pepstatin, leupeptin, and aprotinin; and 10 mM PMSF) and postnuclear supernatants were probed as such or immunoprecipitated using the appropriate polyclonal antibodies and protein A Sepharose (Amersham Biosciences Europe GmbH), or mouse mAb and agarose-conjugated anti-mouse IgG (Sigma-Aldrich srl). Ras activity was measured by in vitro binding assays of postnuclear supernatants from 10 7 cells/sample using GSH-Sepharose bound GST-Raf1. Rac activity was measured by immunoblotting Pak1-specific immunoprecipitates with anti-Rac antibodies. Immunoblots were performed by using peroxidase-labeled secondary antibodies and a chemiluminescence detection kit (Pierce, Rockford, IL). Prestained molecular weight markers were purchased from Life Technologies Italia srl. Proteins were quantitated using a kit from Pierce. Control and simvastatin-treated cells were metabolically labeled for 4 h using 600 µCi (50-62 mCi/mmol) [ 14 C] acetic acid per sample.
Purification of lipid rafts and cholesterol measurements
Lipid rafts were purified from 50 × 10 6 cells/sample by density gradient centrifugation as described (29) . Lysis was performed on ice using 1% Brij-58 or Triton X-100 as detergents. Alternatively, lysis was performed at 37°C using 1% Brij-98 as described (30) . Disruption of rafts was achieved by incubating the cells in serum-free medium for 20 min at 37°C in the presence of 15 mM methyl-β-cyclodextrin prior to cell lysis. Cellular cholesterol was measured in total cell lysates or purified lipid rafts using the Amplex Red Cholesterol Assay kit from Molecular Probes Europe BV (Leiden, the Netherlands).
Flow cytometry
CD3, CD69, and CD25 surface expression on Jurkat cells or PBL was quantitated by flow cytometry using fluorochrome-labeled mAb. To analyze GM1 expression, cells were incubated on ice for 1 h with 15 µg/ml CtxB, then washed, added with a saturating amount of anti-CtxB mAb, and incubated on ice for another 30 min. Bound mAb was revealed using fluorochromeconjugated anti-mouse Ig. Samples were processed using a FACScan flow cytometer (BectonDickinson, San Jose, CA).
Calcium flux was measured using Fluo-4FF (Molecular Probes Europe BV). Cells (10 6 /sample) were suspended in 200 µl RPMI w/o phenol Red (Invitrogen srl) added with 25 mM HEPES, pH 7.4; 5 µM Fluo-4; and 500 µM sulfinpyrazone (Sigma-Aldrich srl). Cells were incubated 45 min at 37°C, pelleted by centrifugation, and resuspended in 500 µl of the same medium without Fluo-4. Baseline fluorescence was recorded for 40 sec at 37°C. Cells were subsequently added with saturating amounts of anti-CD3 mAb and 50 µg/ml secondary antibody. Fluorescence was continously recorded for 512 sec at 37°C. Receptor independent calcium mobilization was determined using the calcium ionophore A23187 (500 ng/ml).
T-cell proliferation was measured by flow cytometric analysis of CFSE-labeled PBL. Cells were resuspended at 20 × 10 6 /ml in PBS and stained with 10 µM CFSE (Molecular Probes Europe BV) for 8 min at room temperature. Cells were subsequently washed twice in RPMI/0.5% FCS, resuspended at 5 × 10 6 /ml, and plated on plastic-bound anti-CD3 mAb, added when required with 5 µg/ml anti-CD28 mAb. Cells were analyzed 24 to 172 h after stimulation following staining with anti-CD3 mAb.
TCR internalization
TCR internalization was quantitated as described (31) . Briefly, cells were incubated on ice with PE-labeled anti-CD3 mAb for 30 min (time 0), washed, and transferred to 37°C for 15 min to 4 h. After stripping residual surface-bound anti-CD3 mAb (10 sec at room temperature in 100 mM glycine, 100 mM NaCl, pH 2.5), internalized anti-CD3 mAb was quantitated by flow cytometry (ARF t , median acid-resistant fluorescence at time "t"). The levels of surface binding at time 0 were quantitated by flow cytometric analysis of a sample taken before tranfer to 37°C (SF, median specific fluorescence). The levels of autofluorescence at time 0 were quantitated by flow cytometry after stripping surface-bound antibody (AF, median aspecific fluorescence). Receptor internalization (SR t , % surface receptor internalized at time "t") was calculated as follows: % SR t = 100 × (ARF t -AF)/(SF-AF).
RESULTS
Simvastatin impairs Ras and Rac association with lipid rafts without significantly affecting intracellular cholesterol levels and lipid raft integrity
Because of their capacity to inhibit an intermediate step in cholesterol biosynthesis, which also controls protein prenylation, statins can potentially affect two key components in TCR signaling: lipid rafts and Ras/Rho family GTPases. To assess the effect of simvastatin on intracellular cholesterol levels, Jurkat T-cells were treated with 20 µM simvastatin for 24 or 48 h, either in the presence of 0.5% serum or in serum-free medium. No differences in the levels of cholesterol were detectable in total cell lysates after 24 h treatment, even when simvastatin treatment was performed in serum-free medium, ruling out a compensation through uptake of cholesterol from extracellular sources. Furthermore, simvastatin did not enhance cholesterol depletion by the cholesterol-sequestering drug methyl-β-cyclodextrin (Fig. 1A) . However, although only minimal effects were observable after 48 h simvastatin treatment in the presence of 0.5% serum, a significant decrease in cellular cholesterol was observed when cells were incubated in serum-free medium (Fig. 1A) . Similar results were obtained when cholesterol was measured in purified lipid rafts (Fig. 1A) . The reduction in cholesterol was paralleled by a modest impairement in cell viability, as quantitated by Trypan blue exclusion (Fig. 1B) and by flow cytometric analysis of cells with subdiploid DNA content (data not shown). Unless specified otherwise, the standard conditions in all the experiments described below were treatment with 20 µM simvastatin for 24 h in the presence of 0.5% serum.
The effect of simvastatin treatment and resulting modulation of cholesterol levels on lipid raft integrity was assessed. Lipid rafts were isolated by sucrose gradient fractionation and tested by immunoblot with antibodies specific for raft-associated proteins. These included the palmytoylated Src kinases Lck and Fyn and the prenylated proteins Ras and Rac. Furthermore, the constitutive weak association of the TCR with lipid rafts (30) was assessed by immunodetection of CD3ζ and CD3ε. Treatment with simvastatin did not affect lipid raft integrity, as shown by the unaltered levels of Lck and Fyn (Fig. 2) . Similar results were obtained when cells were lysed in more stringent conditions (Brij-58, data not shown; Triton X-100, Fig.  2 ). Cell surface expression of ganglioside GM1, which is segregated to lipid rafts, was also not affected by simvastatin treatment, as evaluated by flow cytometry using cholera toxin B/anticholera toxin B antibodies (data not shown). On the other hand, the levels of Ras detectable in lipid rafts were significantly reduced following simvstatin treatment, even in the mildest lysis conditions (Brij-98). This effect was dependent on HMG-CoA reductase inhibition by simvastatin, as it was reversed by addition of mevalonate (Fig. 2) . Furthermore, lipid raft association of Rac, which segregates only in part to this subcellular localization (32) , was also impaired, although the effect of simvastatin was detectable only when cells where lysed in the most stringent conditions (Triton X-100) (Fig. 2) . Similar results were obtained following treatment with simvastatin for 48 h in the presence of serum (data not shown). The impairment in membrane raft association of Ras and Rac is consistent with the known inhibitory effect of statins on protein prenylation (11, 12) . On the other hand, treatment with simvastatin for 48 h in serum-free medium, which results in a reduction in cholesterol levels in lipid rafts (Fig. 1A) , also resulted in lipid raft disruption. Indeed, lipid rafts purified from cells lysed even in the mildest conditions showed not only a further reduction in the levels of Ras and Rac but also lower levels of Lck and a dramatic reduction in CD3ζ (Fig. 3A) . Hence, the effects of statins on membrane localization of Ras and-to a minor extent-of Rac, can be detected in conditions where intracellular cholesterol levels are unaffected, indicating that protein prenylation is exquisitely sensitive to HMG-CoA reductase inhibition in T-cells. This different threshold provides a tool to study the effects of statins on Ras-and Rac-dependent events in the absence of more generalized effects dependent on lipid raft integrity.
Simvastatin inhibits TCR-dependent activation of the Ras/MAP kinase pathway
To address the impact on TCR signaling of the decreased association of Ras with lipid rafts induced by simvastatin, Ras activity was measured by pull-down assays using a GST-Raf1 fusion protein, which selectively interacts with GTP-bound, active Ras. As shown in Fig. 4A , simvastatin treatment resulted in inhibition of TCR-dependent Ras activation. The inhibitory effect of simvastatin was reversed by mevalonate, indicating that it was dependent on inhibition of HMG-CoA reductase. These results are consistent with the requirement for prenylationdependent membrane localization in Ras function (7).
Activation of Ras results in the initiation of a serine-threonine cascade involving sequentially Raf, MEK and Erk (8) . The outcome of Ras inhibition by simvastatin on TCR-dependent activation of the MAP kinase pathway was addressed by immunoblot analysis of total cell lysates with antibodies against the phosphorylated, active forms of the proteins. In agreement with the block of Ras activation, MAP kinase activation was dramatically inhibited by simvastatin and this effect was reversed by mevalonate ( Fig. 4B-D) . Similar results were obtained on freshly purified human peripheral blood lymphocytes (PBL, data not shown). Furthermore, flow cytometric analysis showed that surface expression of the early activation marker CD69, which is induced by TCR engagement and is strictly dependent on Ras, was significantly reduced following simvastatin treatment in Jurkat cells (Fig. 5A ). Reduction both in the relative percentage of CD69 + cells and in the levels of CD69 expressed on the plasma membrane following TCR ligation was also observed in human PBL treated with simvastatin (Fig. 5B) . Similar results were obtained in PBL when expression of CD25, the high-affinity IL-2 receptor, was analyzed (Fig. 5B) . These effects were reversed, at least in part, by the addition of mevalonate (Fig. 5 ). In agreement with this finding, peripheral T lymphocyte proliferation induced either by CD3 cross-linking on plate-bound antibody, or by CD3/CD28 co-stimulation, was dramatically suppressed, as revealed by flow cytometric analysis of CFSE-labeled PBL (Fig.  5C ). The block in T-cell proliferation was reversed by mevalonate (data not shown).
Simvastatin selectively affects Ras activity by inhibiting its prenylation in conditions which do not impair tyrosine kinase-dependent TCR signaling
Activation of Ras is the endpoint of a protein tyrosine phosphorylation cascade initiated by TCR engagement and orchestrated by Src, Syk, and Tec family tyrosine kinases, which promote recruitment to the plasma membrane of the guanine nucleotide exchangers Sos and RasGRP, resulting in the conversion of Ras to its GTP-bound, active form (33, 34) . Lipid rafts represent the platform where the multimolecular assemblies promoted by TCR engagement are generated and stabilized (5) . Although simvastatin treatment for 24 h did not appear to affect raft integrity, the possibility of an impairment of early tyrosine kinase-dependent events leading to Ras activation was addressed. As shown in Fig. 6A , phosphorylation of CD3ζ, which permits recruitment of ZAP-70, was not affected by simvastatin. In agreement with this result, tyrosine phosphorylation of ZAP-70 was not impaired (Fig. 6B) . Tyrosine phosphorylation of LAT, which plays a primary role in Grb2/Sos recruitment, was also analyzed. No significant effect of simvastatin on this event was observed (Fig. 6C) . Furthermore, TCR-dependent calcium mobilization, which requires lipid raft integrity and protein tyrosine kinase signaling (5, 33), was not affected by simvastatin (data not shown). Of note, treatment with simvastatin for 48 h in serum-free medium, which results in decreased cholesterol levels and lipid raft disruption, profoundly inhibits early tyrosine kinase dependent events, as shown by the dramatic inhibition of CD3ζ phosphorylation and ZAP-70 recruitment (Fig. 3B) , further underlining the crucial role of lipid rafts in TCR signaling.
While the above data rule out a defect in TCR signaling upstream of Ras in simvastatin-treated cells, the impairment in TCR-dependent Ras/MAP kinase signaling, as well as its reversal by mevalonate, strongly suggests that simvastatin directly affects Ras function as the result of HMG-CoA reductase inhibition. Mevalonate is indeed the precursor of farnesylpyrophosphate, which is post-translationally added to Ras, resulting in its localization to the inner leaflet of the plasma membrane, an essential requirement for Ras function (7). To address this issue, the most downstream event in Ras/MAP kinase signaling, Erk activation, was tested in cells treated with simvastatin in the presence of farnesylpyrophosphate (FPP). Squalene, an intermediate in the cholesterol biosynthetic pathway downstream of mevalonate and FPP (2), was used as a negative control. As shown in Fig. 7A , inhibition of TCR-dependent Erk activation by simvastatin was fully reversed by FPP, but not by squalene, supporting the notion that simvastatin inhibits Ras farnesylation, resulting in impaired membrane localization and activity. Indeed, immunoblot analysis of lipid rafts purified from cells treated with simvastatin in the presence of FPP showed full recovery of Ras localization in membrane rafts (Fig. 7C) , indicating that simvastatin interferes with this process by inhibiting Ras prenylation. Accordingly, a shift in electrophoretic mobility of Ras, which results from C-terminal processing following covalent addition of the lipid moiety to the C-terminal cysteine residue by farnesyltransferases (7), could be observed in simvastatin-treated cells, but not in cells treated with a combination of simvastatin and mevalonate (Fig. 7D, left) . Furthermore, notwithstanding the extremely weak labeling, analysis of [
14 C] incorporation in Ras-specific immunoprecipitates from cells metabolically labeled with [ 14 C]-acetic acid, the precursor of acetyl-CoA, which is used by HMG-CoA reductase in the biosynthesis of mevalonate and subsequently incorporated into FPP and GGPP, showed that simvastatin inhibited Ras lipidation (Fig. 7D, right) . Interestingly, geranylgeranylpyrophosphate (GGPP), an isoprenoid resulting from the modification of FPP, also recovered TCR-dependent Erk activation (Fig. 7A) , as well as activation of the upstream kinases MEK and Raf (data not shown). Analysis of Ras association with lipid rafts from cells treated with simvastatin in the presence of GGPP showed that the simvastatin-dependent impairment in Ras membrane localization was fully overcome by GGPP (Fig. 7C) , indicating that, in the absence of FPP, an alternative mechanism of Ras prenylation becomes operational. This possibility is supported by the finding that Ras is geranylgeranylated when FPP is limiting (35, 36) .
Simvastatin inhibits TCR-dependent activation of the stress kinase pathway
TCR signaling involves, besides Ras, Rho family GTPases. Among these, Rac is critically required for re-organization of cortical actin at the immunological synapse (37) . Rho family GTPases have been identified as targets of statins in other cells types (16) (17) (18) (19) (20) (21) . The effect of simvastatin on TCR-dependent Rac activation was tested by analyzing its association with Pak1, which selectively interacts with GTP-bound, active Rac (22) . As shown in Fig. 8A , immunoblot analysis of Pak1 specific immunoprecipitates with anti-Rac antibodies showed that Rac activity was significantly inhibited in simvastatin treated cells. The inhibition was reversed by mevalonate, indicating that simvastatin directly affects Rac function as the result of HMG-CoA reductase inhibition. In agreement with this result, TCR-dependent activation of the stress kinase p38, which is the endpoint of a serine/threonine kinase cascade triggered by Rac/Pak1 complexes (22) , was significantly reduced in cells treated with simvastatin (Fig. 8B ). Complete reversal of the inhibitory effect of simvastatin on p38 activation was achieved by mevalonate ( Fig. 8B) , as well as GGPP, but not by squalene (Fig. 7B) , which suggests that the inhibitory effect of simvastatin on p38 activation results from defective geranylgeranylation of Rac and subsequent impairment in its subcellular localization. Indeed, immunoblot analysis with anti-Rac antibodies of lipid rafts purified from cells treated with simvastatin in the presence of GGPP showed that GGPP reverted the impairment in membrane localization of Rac (Fig. 7C) (Fig. 7D, right) . Tyrosine kinase-dependent TCR signaling upstream of Rac, including tyrosine phosphorylation of the Rho family exchange factor Vav, was conversely not affected by simvastatin treatment (Fig. 6 and Fig. 8C ).
Interestingly, complete recovery of TCR-dependent p38 activation was also observed in the presence of FPP, which, albeit upstream of GGPP, is not sufficient for its biosynthesis (Fig. 7B ).
Immunoblot analysis of lipid rafts purified from cells treated with simvastatin in the presence of FPP failed to show recovery of Rac association with membrane rafts (Fig. 7C ). This result indicates that, as opposed to Ras, Rac association with lipid rafts cannot occur through the addition of an alternative prenyl group. Furthermore, the data suggest that Ras or another farnesylated protein may couple the TCR to stress kinase activation independently of Rac.
Simvastatin inhibits ligand-dependent TCR internalization
TCR internalization is a key element in productive TCR signaling. First, removal of fired TCR/CD3 complexes from the T-cell surface leaves the previously engaged MHC/peptide free to interact with another TCR. This process, known as "serial triggering", results in effective achievement of productive signaling by the very few MHC complexes bearing specific peptide antigen on the antigen presenting cell (38) . Furthermore, although signaling persists for some time after receptor endocytosis, TCR internalization eventually results in signal termination and thereby contributes to a tight control of the activation state of the TCR signaling cascade (39) .
Receptor endocytosis is regulated by Rab GTPases (10) . Similarly to other small GTP binding proteins, Rab proteins are post-translationally modified by prenylation, and specifically by geranylgeranylation, and as such are potential targets of statins. To address the effects of simvastatin on TCR internalization, Jurkat T-cells were incubated on ice with saturating amounts of FITC-labeled anti-CD3 mAb to achieve full TCR occupancy, and subsequently shifted to 37°C for different lengths of time. Internalized TCR/anti-CD3 mAb complexes were quantitated by flow cytometry after stripping the cells of surface-bound anti-CD3 mAb. As shown in Fig. 9 , simvastatin treatment resulted in a significant reduction in receptor endocytosis at all time points analyzed. This inhibition was fully reversed by mevalonate. Hence simvastatin blocks liganddependent receptor endocytosis, an effect that is likely to result from defective membrane targeting of Rab proteins.
Collectively, the data indicate that, in conditions where no significant effects on lipid rafts can be observed, simvastatin impairs TCR signaling by selectively disrupting the pathways regulated by small GTPases, including the Ras/MAP kinase pathway, the Rac/stress kinase pathway, and the Rab dependent pathway of receptor endocytosis.
DISCUSSION
The immunosuppressive activities of statins are well documented and have possible important clinical relevance, as underlined by reports of improved outcome among solid organ transplant recipients (40, 41) as well as the recent report of a decline in neurological lesions in a cohort of multiple sclerosis patients (42) . The molecular basis of immunosuppression by statins is, however, as yet not fully established. Allosteric inhibition of LFA-1 binding to ICAM-1 by statins independent of their activity on HMG-CoA reductase provides a clear-cut mechanism of T-cell immunosuppression. LFA-1 is mobilized to the immunological synapse following TCR engagement by MHC-bound peptide antigen on antigen presenting cells (37) . In this location, characterized by a precise molecular geometry, LFA-1 provides a potent costimulatory signal by promoting reorganization of the actin cytoskeleton through a tyrosine kinase-dependent signaling pathway ultimately coupled to the activation of gene expression (24) .
The TCR/CD3 complex, which triggers the primary signal, is, however, coupled to an intracellular signaling cascade where a number of steps are potential targets of statins. Lipid rafts play a key role in immunoreceptor signaling as the plasma membrane localization where the activated TCR becomes juxtaposed to molecular components constitutively associated to lipid rafts and essential for productive signaling, including Lck, which permits initiation of TCR signaling by phosphorylation of CD3ζ, and the LAT transmembrane adaptor, which, once phosphorylated on tyrosine residues, becomes a scaffold for multimolecular assemblies (5).
Lipid raft disruption results in impaired initiation and propagation of TCR signaling (5), suggesting that the cholesterol-lowering properties of statins may contribute to their immunosuppressive activity. Another potential target of statins, which also involves their capacity to block HMG-CoA reductase activity, is the Ras GTPase superfamily. Ras and Rasrelated proteins require prenylation for localization to the plasma membrane, where they become activated by specific guanine nucleotide exchange factors and in turn initiate serine-threonine kinase cascades leading to transcription factor activation (9, 43) . Our data show that simvastatin can block T-cell activation through two independent mechanisms, both of which involve HMGCoA reductase and affect the TCR signaling cascade. First, simvastatin inhibits the activation of Ras and Rac, which are both crucially required for T-cell activation (27) , by preventing their prenylation and, therefore, their correct positioning at the plasma membrane. Furthermore, although the effects of simvastatin on Rab activation have not been formally addressed, TCR internalization, which is controlled by Rab GTPases (44), is also inhibited by simvastatin. Second, prolonged simvastatin treatment in the absence of exogenous cholesterol results in perturbation of lipid rafts, as shown by the decreased raft association of the Src kinases Lck and Fyn, which are post-translationally modified by the addition of lipid moieties other than prenyl chains (45) and require HMG-CoA reductase activity indirectly because of its key role in cholesterol biosynthesis and, therefore, in the formation of lipid rafts. Hence, simvastatinmediated immunosuppression can be accounted for by pleiotropic negative effects on TCR signaling, based on its capacity to block both cholesterol biosynthesis and protein prenylation. In this context, lovastatin has been reported to impair both post-translational modification of Ras and early events in TCR signaling, including calcium mobilization and inositol phosphate production, two events that require lipid raft integrity (46) . On the other hand, while inhibition of FcεRI signaling in mast cells by lovastatin has also been reported, in these cells lovastatin treatment results in selective inhibition of Rho GTPases downstream of the tyrosine kinase cascade triggered by FcεRI (47), suggesting that, according to their potency and the specific cellular context, different statins may affect to a different extent intracellular signaling controlled by rafts and by Ras-like GTPases, respectively. Because of the important and general role of both lipid rafts and Ras/Rho proteins, as well as Rab proteins, in immunoreceptor signaling (5, 27) , it is likely that statins will be found to affect other cell populations within the immune system.
The different threshold in the T-cell responses to simvastatin is noteworthy. Twenty-four hour treatment with simvastatin is sufficient to impair both lipid raft localization and function of Ras and Rac proteins, as well as receptor mediated endocytosis, with no obvious effect on lipid raft integrity, indicating that these effects result from defective prenylation of Ras and Ras-like proteins. Lipid raft disruption can be observed only after prolonged simvastatin treatment in the absence of serum, which results in cellular cholesterol depletion, suggesting the existence of a compensation process through uptake of extracellular cholesterol, which, while restoring in part cellular membranes, will not, however, restore protein prenylation. Although it is difficult to compare the conditions used for T-cell activation in vitro with the actual bioavailabity of statins in patients under chronic treatment, it can be hypothesized that, in the physiological context of circulating blood, where cholesterol is not limiting and can therefore counterbalance the reduced intracellular cholesterol biosynthesis, simvastatin will block T-cell activation prevalently by inhibiting Ras superfamily GTPases. The latter effect can be realistically hypothesized based on the serum concentrations of simvastatin, which have been calculated in the µM range, in patients where immunomodulation by this statin has been documented (42, 48) . Of note, an opposite differential sensitivity to lovastatin of cholesterol biosynthesis and Ras prenylation was observed in CHO cells (49) , suggesting that either the quantitative balance of the pathways downstream of HMG-CoA reductase leading respectively to isoprenylation and cholesterol production, or the level of protein prenylation, might be differentially modulated in different cells types. Alternatively, the significantly larger size of epithelial cells compared with T-cells, and the resulting increased membrane biosynthetic activity, might account for the higher sensitivity of these cells to cholesterol depletion.
Although the reversal by exogenous mevalonate of the simvastatin dependent inhibition of the serine-threonine kinase cascades coupled to Ras and Rac demonstrates that this immunosuppressive property of simvastatin depends on its capacity to block HMG-CoA reductase, the results obtained using FPP and GGPP are in part unexpected. FPP is an intermediate in the cholesterol biosynthetic pathway downstream of mevalonate, and is the precursor of both cholesterol and GGPP. However, generation of GGPP involves condensation of FPP with isopentenyl pyrophosphate, another product of mevalonate catabolism (2) . Hence, FPP and GGPP are expected to selectively overcome the simvastatin block to Ras farnesylation and to Rac geranylgeranylation, respectively. Because "classical" MAP kinases are believed to be coupled to Ras, and stress-activated kinases to Rho GTPases, recovery of Erk activation by FPP and of p38 activation by GGPP was expected. Surprisingly, treatment with exogenous FPP and GGPP resulted in full reversal of the simvastatin-dependent inhibition of both Erk and p38. In the case of Ras, the recovery of Ras/MAP kinase signaling by GGPP can be accounted for by a salvage pathway involving the compensatory prenylation of Ras by the addition of a geranylgeranyl moiety, which results in its correct localization at the plasma membrane (35, 36) . However, treatment with FPP fails to recover Rac association with the plasma membrane, suggesting that Ras, either directly of through a member of the respective MAP kinase pathway, participates in the activation of p38 independently of Rac. Alternatively, another farnesylated protein may account for the reversal of the simvastatin dependent inhibition of p38 activation.
Recent clinical reports both on solid organ transplant recipients and on multiple sclerosis patients indicate that statins display immunomodulating activities also in vivo (40) (41) (42) . Notwithstanding the spread of clinical applications of statins beyond hypercholesterolemia and related diseases, the mechanisms underlying statin mediated immunosuppression are as yet not fully understood. We believe that our data contribute novel insight into the mechanisms underlying suppression of T-cell activation by statins and provide a solid scientific rationale to recommend the design of controlled clinical trials concerning the treatment of autoimmune diseases with statins. 
